MATTHEW SAVAGE: Open Payments
NPI 1407637457 · ALBANY, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$374 in 21 payments from 9 companies in 2025. Trend: 2023 $14 · 2024 $138 · 2025 $374
Food & beverage: $374
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 4 | $83 |
| ABBVIE INC. | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
| Gilead Sciences, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Exact Sciences Corporation | 1 | $14 |
Products named: FANAPT, REXULTI, VRAYLAR, CAPLYTA, ABILIFY MAINTENA, Auvelity, Veozah, QULIPTA.
Industry payments across KY — which companies pay providers there.
